Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

inTest Shares: A Silver Lining Amidst a Sharp Decline

Robert Sasse by Robert Sasse
November 8, 2025
in Earnings, Semiconductors, Tech & Software
0
inTest Stock
0
SHARES
135
VIEWS
Share on FacebookShare on Twitter

Following a disappointing quarterly earnings report, inTest Corporation’s stock experienced a significant sell-off. Although revenues fell short of expectations, prompting a drop of over 13% in the share price, a surprising surge in new orders provided a glimmer of hope for investors.

Order Intake Reveals Underlying Strength

Despite the negative headlines, a deeper look reveals a powerful counter-narrative. The company’s order intake exploded, soaring 34.2% year-over-year to reach $37.6 million. This marks the highest level seen since the second quarter of 2022. Even more impressive is the backlog, which climbed to a near-record $49.3 million.

Key order metrics include:
* Order Intake: Increased 34.2% compared to the prior year.
* Order Backlog: Reached $49.3 million.
* Key Drivers: Robust demand from the automotive/electric vehicle and defense/aerospace sectors.

Company management attributed the quarter’s revenue shortfall to technical issues that delayed the completion and shipment of several systems, amounting to approximately $2 million. They confirmed these issues have since been resolved and the delayed systems have been delivered to customers.

Quarterly Results Trigger Market Sell-Off

The initial figures from the third quarter were undeniably sobering for the market. Revenue of $26.2 million missed analyst forecasts of $29.09 million by nearly 10%. The situation was more severe on the bottom line; instead of the anticipated adjusted earnings of 3 to 4 cents per share, the company reported a loss of 2 cents per share.

Should investors sell immediately? Or is it worth buying inTest?

The market’s reaction was swift and severe. The stock plummeted over a two-day selling frenzy. It first fell 3.7% in pre-market trading, followed by a daily loss of 6.94% to close at $8.05. The downward trend continued the next day, with shares dropping another 6.42% to settle at $7.72. Cumulatively, this represented a loss exceeding 13% in just 48 hours.

Advertisement:

For those interested in turnaround opportunities like inTest – a complimentary report highlights three tech stocks with significant comeback potential. Download the Tech Comeback Report Now

Analyst Confidence and Future Outlook

Can the stock recover from this setback? The signs are not unfavorable. Lake Street Capital Markets expressed continued confidence, raising its price target from $8 to $10 while maintaining a “Buy” rating. The average analyst price target stands at $10, suggesting substantial upside potential from the current level around $7.72.

Looking ahead, the company’s own guidance for the fourth quarter anticipates a recovery, with projected revenues between $30 and $32 million. From a technical perspective, chart support levels are identified around $7.10 and $7.00. The next major test for the company will come in February 2026 with the release of its full-year financial results.

Ad

inTest Stock: Buy or Sell?! New inTest Analysis from February 7 delivers the answer:

The latest inTest figures speak for themselves: Urgent action needed for inTest investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

inTest: Buy or sell? Read more here...

Tags: inTest
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock
Blockchain

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Next Post
Bitcoin Stock

Bitcoin Plunges to Lowest Level in a Year Amid Divergent Investor Sentiment

Diginex Stock

Diginex Accelerates Growth Strategy with Edge AI Acquisition

Metaplanet Stock

Metaplanet Accelerates Bitcoin Acquisition Strategy with Major Debt Financing

Recommended

Jakks Pacific Reports Disappointing Q4 2023 Earnings

2 years ago
Ecommerce Stock Exchange

Notable Options Market Activity for Shopify

2 years ago
Fannie Mae Stock

Fannie Mae’s Public Offering Plans Derailed by Prominent Investor

3 months ago
Ocugen Stock

Ocugen Shares Face Critical Test Amid Steep Decline

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Trending

Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

by Rodolfo Hanigan
February 7, 2026
0

Investors in Viking Therapeutics are currently focused on a specific calendar event rather than breaking news. The...

Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment
  • Diginex Enters Critical Implementation Phase Following Strategic Moves
  • Deluxe Stock Gains Momentum on Successful Fintech Transition

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com